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Abstract: We know that one of the main risk factors for cervical cancer is an infection with high-risk
human papillomavirus (HR-HPV). Prostaglandins and their receptors are very important for the
tumour growth and tumour-associated angiogenesis. Little is known about the expression of the
Prostaglandin E receptor type 3 (EP3) or the Prostaglandin (PG)E2-EP3 signalling in cervical cancer,
so the aim of the study was to analyse the expression of the EP3 receptor in cervical cancer and find
prognostic factors in relation to survival; EP3 immunohistological staining of 250 cervical cancer slides
was performed and analysed with a semi-quantitative score. The statistical evaluation was performed
with Statistical Package for the Social Sciences (SPSS) to evaluate the staining results and the survival
analyses of the cervical cancer cases. A significant difference was observed in EP3 expression in
Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stadium I versus FIGO stadium
II–IV cases. High expression of EP3 (IRS ≥ 1.5) in cervical cancer patients was correlated with
poor prognosis in overall survival rates. Survival in adenocarcinoma (AC) of the cervix was lower
than in squamous cell carcinoma (SCC). Cox regression analysis shows that EP3 is an independent
prognosticator. In this study we could show that the membrane-bound prostaglandin receptor EP3
is an independent prognosticator for cervical cancer patient survival. Targeting the EP3 receptor
seems to be an interesting candidate for endocrine therapy. Therefore, more research is needed on the
influence of the receptor system and its influence on cervical cancer growth.
Keywords: cervical cancer; squamous cell carcinoma; adenocarcinoma; EP3 receptor; overall survival;
prognostic factor; cox regression
1. Introduction
Approximately half a million women are diagnosed annually with invasive cervical cancer
worldwide. In the year 2012 we had about 530,000 new cases, which is about 8% of all female cancer
deaths [1]. The infection with genital human papillomavirus (HPV) is one of the most common
sexually-transmitted infections worldwide [2]. We know that one of the main risk factors for cervical
cancer is an infection with high-risk human papillomavirus (HR-HPV). Especially HPV-16 and HPV-18
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subtypes cause nearly 70% of all cases of cervical cancer [3]. The most common HPV subtypes in
woman with normal cytological findings are HPV-16, HPV-18, HPV-52, HPV-31, and HPV-58 [2].
Prostanoids are metabolites of arachidonic acid synthesized by cyclooxygenase-1 (COX-1) and
cyclooxygenase-2 (COX-2) [4]. The prostaglandin (PG) D2, PGE2, PGF2α, PGI2, and the thromboxane
A2 are found in most tissues and organs. They are produced by almost all nucleated cells and act as
autocrine and paracrine lipid mediators [5]. Each prostaglandin has, as a ligand, its own receptor.
The receptor for the PGE2, named EP receptor, has four subtypes (EP1, EP2, EP3, EP4). The receptors
are G protein-coupled receptors with seven transmembrane domains [6]. The prostaglandins play
an important role in the induction of fever, pain, infection, immunity, and the stimulation of the
hypothalamic-pituitary-adrenal axis [7]. Some of the prostaglandins are implicated in many aspects
of reproductive functions. In addition the PG play an important role in vascular homeostasis,
like inducing hypertension, thrombosis, and haemostasis [6].
The prostaglandins and their receptors are very important for tumour growth and
tumour-associated angiogenesis. However, the identity of the responsible prostaglandins and the
prostaglandin receptors is at the moment unknown [8]. Amano et al. characterized the role of
PG-signalling in tumour-associated angiogenesis and tumour progression in a mouse model and
declare that the PGE2-EP3 signalling is critical for tumour-associated angiogenesis and tumour
growth [8]. Recent studies suggest that many tumours are regulated by COX enzyme products [9].
COX-2 is upregulated in numerous cancers like pancreas, lung, bladder, colon, and prostate [10].
The EP3 receptor subtype is very special among the EP receptors, because in that there are multiple
isoforms generated through mRNA splicing. So various splicing variants have been identified [11–13].
The different isoforms differ in the C-terminus and through different signal transduction pathways [13].
Regarding the EP3 isoforms and their effects, little is known and their different physiological roles
remain unknown [12].
Little is known about the expression of the EP3 receptor or the PGE2-EP3 signalling in cervical
cancer. A few studies suggest the overexpression of COX-2 in cervical cancer [14]. However,
the mechanism of the upregulation of COX-2 in cervical cancer remains unknown [15].
The aim of this study was a systematic analysis of the expression of the EP3 receptor in human
squamous cell carcinomas and adenocarcinomas of the cervix. In addition, we want to investigate if
there exists some prognostic factors in relation to survival. A selective EP3 antagonist may exhibit a
chemoprotective effect and, in the future, it could become a new important tool for cancer therapy [8].
2. Results
2.1. Positive Control of EP3 Staining
Paraffin-embedded sections of ovarian carcinoma metastasis in the colon were used to control the
quality of the EP3 staining (Figure 1A,B). The anti-PTGER3 antibody binding site, the first cytoplasmatic
domain with the amino acid sequence: RRESKRKKSFLLC position 79−91 is present in all EP3 isoforms
1–12 and was picked after researching the Human Protein Atlas.
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Figure 1. All images are at 10× magnification with an insert at 25× magnification. (A) Positive control 
of ovarian cancer metastasis in the colon shows cystoplasmatic and membrane-associated staining; 
(B) Negative control of ovarian cancer metastasis in the colon; (C) Squamous cell carcinoma 
Immunoreactive score (IRS) 1; (D) Adenocarcinoma IRS 1; (E) Squamous cell carcinoma IRS 4;  
(F) Adenocarcinoma IRS 4; (G) Adenocarcinoma carcinoma IRS 8; (H) Squamous cell carcinoma IRS 
8, (I) Squamous cell carcinoma IRS 9; (J) Prostaglandin E receptor type 3 (EP3) staining of an 
Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) Ib diagnosed IRS 2 stained 
squamous cell carcinoma; (K) EP3 staining of an FIGO 4 diagnosed IRS 4 stained squamous cell 
carcinoma; (L) Boxplot of FIGO I and FIGO II–IV cases with median IRS. 
2.2. EP3 Staining in Cervical Carcinoma 
The intensity of the expression was evaluated by the immunoreactive score (IRS) using a Leitz 
(Wetzlar, Germany) microscope, and is well-established and applied in numerous other studies. In brief, 
this semi-quantitative score multiplies the intensity of the staining (0 = not stained; 1 = low intensity; 2 = 
moderate intensity; 3 = high intensity) and the percentage of stained cells (0 = 0%; 1 = 1–10%; 2 = 11–50%; 
3 = 51–80%; 4 ≥ 80%). Finally, we distinguished between 0 = no expression and 12 = very high 
expression of EP3 [16]. Two independent observers were blinded and evaluated the intensity and 
Figure 1. All images are at 10× magnification with an insert at 25× magnification. (A) Positive
control of ovarian cancer metastasis in the colon shows cystoplasmatic and membrane-associated
staining; (B) Negative control of ovarian cancer metastasis in the colon; (C) Squa ous cell carcinoma
Im unoreactive score (IRS) 1; (D) Adenocarcinoma IRS 1; (E) Squamous cell carcinoma IRS 4;
(F) Adenocarcinoma IRS 4; (G) Adenocarcinoma carcinoma IRS 8; (H) Squamous cell carcinoma IRS 8,
(I) Squamous cell carcinoma IRS 9; (J) Prostaglandin E receptor type 3 (EP3) staining of an Fédération
Internationale de Gynécologie et d’Obstétrique (FIGO) Ib diagnosed IRS 2 stained squamous cell
carcinoma; (K) EP3 staining of an FIGO 4 diagnosed IRS 4 stained squamous cell carci oma; (L) B xplot
of FIGO I and FIGO II–IV cases with median IRS.
2.2. EP3 Staining in Cervical Carcinoma
The intensity of the expression was evaluated by the immunoreactive score (IRS) using a Leitz
(Wetzlar, Germany) microscope, and is well-established and applied in numerous other studies. In brief,
this semi-quantitative score multiplies the intensity of the staining (0 = not stained; 1 = low intensity;
2 = moderate intensity; 3 = high intensity) and the percentage of stained cells (0 = 0%; 1 = 1–10%;
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2 = 11–50%; 3 = 51–80%; 4 ≥ 80%). Finally, we distinguished between 0 = no expression and 12 = very
high expression of EP3 [16]. Two independent observers were blinded and evaluated the intensity and
distribution pattern of the immunochemical staining reaction. The two observers differed in eight
cases (n = 3.2%) of the evaluation. These cases were re-evaluated together and both observers came to
the same result. The concordance before the re-evaluation was 96.8%.
A total of 77.2% of all cervical cancer specimens showed cytosolic expression of EP3. The IRS was
2.75 in 76% of the samples, compared to cases that did not express EP3 (18.0%) at all. Compared to
21.1% with low expression (IRS < 1.5), an enhanced staining (IRS ≥ 1.5) was detected in 78.9% of the
samples. The cut off of IRS 1.5 was obtained through receiver operator curve (ROC) analysis. We found
significant positive correlation using Spearman’s test between EP3 IRS staining and tumor size (pT)
(p = 0.018; Rho = 0.154) and FIGO stadium (p = 0.040; Rho = 0.133).
We separated two groups regarding invasiveness: FIGO stadium patients with the diagnosis of
FIGO I, IA, IB (Figure 1J) which have a limited tumour in the cervical part of the uterus and the second
group with FIGO II, III, IV (Figure 1K) stadium. The result was that the first group of 57 cases had a
median EP3 IRS score of 2 and the second group of 91 cases showed a median EP3 IRS score of 4 with
a significance of p = 0.012 (Figure 1L).
2.3. Correlation Analysis between Prostaglandin E Receptor Type 3 (EP3) and Fédération Internationale de
Gynécologie et d’Obstétrique (FIGO) Classification
We examined the correlation between EP3 and several clinic pathological parameters, such as
grading, histology, size of the primary tumour (T-status), nearby lymph nodes (N-status),
and FIGO-classification by noticing the distribution of these parameters in our study group. In addition,
a significant difference was observed in EP3 expression in FIGO stadium I cases versus FIGO stadium
II–IV cases (Table 1).
Table 1. EP3 Immunoreactive score (IRS) staining results and correlation analysis, pN = lymph node
stage, pT = tumour stage, FIGO = Fédération Internationale de Gynécologie et d’Obstétrique.
Variables p (NPAR) Correlation Coefficient
Histology 0.700 (−0.025)
pN 0.229 0.078
pT 0.018 0.154
FIGO 0.040 0.133
2.4. Role of EP3 for Overall Survival
Enhanced EP3 expression (IRS≥ 1.5, obtained by ROC-analysis) was associated with shorter survival
time after diagnosis. As shown in the Kaplan-Meier curve (Figure 2A), high expression of EP3 (IRS≥ 1.5)
in cervical cancer patients was correlated with poor prognosis in overall survival rates (p = 0.012).
2.5. Survival Function of Squamous Cell Carcinoma Versus Adenocarcinoma
Additionally, we compared the cumulative survival of all EP3-positive (IRS ≥ 1.5) squamous
cell carcinomas versus adenocarcinomas. The Kaplan-Meier curve (Figure 2B) shows, as expected,
that adenocarcinoma patients have a poor survival time after diagnosis p = 0.009 [17].
2.6. EP3 Staining of Squamous Cell Carcinoma Versus Adenocarcinoma
In addition, we performed a Kaplan-Meier test for EP3 positive (IRS ≥ 1.5) squamous cell
carcinoma and adenocarcinomas versus their EP3 negative ones and were able to show that EP3
expression in squamous carcinoma patients is significant with poor survival (p = 0.003; Figure 2C).
Overall survival in cervical adenocarcinomas indicates that none of the EP3 negative patients in our
collective died (Figure 2D).
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Figure 2. Kaplan-Meier curves: (A) EP3 survival function of all cervical cancer carcinoma p = 0.012; 
(B) EP3 survival function of all cervical squamous-versus adenocarcinoma p = 0.009; (C) EP3 survival 
function of cervical squamous cell carcinoma diagnosed patients p = 0.003; (D) EP3 survival function 
of cervical adenocarcinomas patients p = 0.003. 
2.7. Cox Regression of EP3 Immunoreactive Score (IRS) with Clinic Pathological Variables 
The additionally performed multivariate cox-regression tested which histopathological 
parameter were independent prognosticators for survival in our study group. 
For overall survival the histological subtype (p = 0.002), lymph node metastasis (pN)-status (p = 
0.025) and tumor size (pT)-status (p = 0.001) were independent prognosticators (Table 2). 
Table 2. Cox regression of clinic pathological variables regarding overall survival, pM = distant 
metastasis stage, IRS = Immunoreactive score, CI = confidence interval, Exp (B) = hazard ratio. 
Variable Significance 
Hazard Ratio 
of Exp (B) 
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Histology 0.002 3.118 1.538 6.322 1.137 
pT 0.001 1.32 1.115 1.562 0.277 
pN 0.025 2.208 1.103 4.42 0.792 
FIGO 0.398 0.971 0.905 1.04 −0.030 
Grading 0.242 1.381 0.804 2.372 0.323 
Age 0.136 1.021 0.993 1.05 0.021 
pM 0.261 2.214 0.554 8.857 2.214 
  
Figure 2. Kaplan-Meier curves: (A) EP3 survival function of all cervical cancer carcinoma p = 0.012;
(B) EP3 survival function of all cervical squamous-versus adenocarcinoma p = 0.009; (C) EP3 survival
function of cervical squamous cell carcinoma diagnosed patients p = 0.003; (D) EP3 survival function of
cervical adenocarcinomas patients p = 0.003.
2.7. Cox Regression of EP3 Immunoreactive Score (IRS) with Clinic Pathological Variables
The additionally performed multivariate cox-regression tested which histopathological parameter
were independent prognosticators for survival in our study group.
For overall survival the histological subtype (p = 0.002), lymph node metastasis (pN)-status
(p = 0.025) and tumor size (pT)-status (p = 0.001) were independent prognosticators (Table 2).
Table 2. Cox regression of clinic pathological variables regarding overall survival, pM = distant
metastasis stage, IRS = Immunoreactive score, CI = confidence interval, Exp (B) = hazard ratio.
Variable Significance Hazard Ratio of Exp (B) Lower 95% CI of Exp (B) Upper 95% CI of Exp (B) B
EP3 IRS 0.007 1.264 1.066 1.498 0.234
Histology 0.002 . 1.538 6.322 1.137
pT 0.001 . .115 1.562 0.277
pN 0.025 . 1.103 4.42 0.792
FIGO 0.398 0.971 0.905 1.04 −0.030
Grading 0.242 1.381 0.804 2.372 0.323
Age 0.136 1.021 0.993 1.05 0.021
pM 0.261 2.214 0.554 8.857 2.214
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3. Discussion
In recent years, attention has been focused on understanding the role of inflammation in tumour
biology. It is known that COX-2 plays an important role for the induction of inflammation either
individually or through sustained production of PGE2 [18]. The overexpression of COX-2 is reported
in numerous human malignancies including colon, breast, lung, and prostate [19]. It is even reported
that COX-2 is overexpressed in HPV-related diseases, like cervical cancer [20].
In our investigation we examined the expression of EP3 receptor in cervical cancer
(adenocarcinoma and squamous cell carcinoma), the EP3 receptor as an independent marker and tried
to find prognostic factors in relation to survival.
Within this study, we showed that the immunohistochemical evaluation of EP3 receptor staining
was correlated with high FIGO-classification in cervical cancer. This is in line with prognostic
implications of higher EP3 receptor expression and higher FIGO-classification, which are both
associated with poorer survival. We demonstrated that an increased EP3 receptor expression correlates
with a negative outcome of overall survival of cervical carcinoma patients.
Further studies suggest that tumour histology has an important impact on survival for women
with cervical cancer and, additionally, a poorer survival in patients with cervical adenocarcinoma [21].
We find the same results but, additionally, we could demonstrate that patients with adenocarcinoma
and an IRS less than 1.5 had a very good overall survival rate. It is useful to distinguish between
patients with AC and patients with AC and a high expression of EP3 receptor too, because the latter
had a significantly worse outcome regarding survival. Thus, targeting the EP3 receptor, diagnostically,
generally seems possible. On the other hand a new study from 2017 suggest that there was no
significant difference in survival when patients were compared by cell type, so the prognosis of
adenocarcinoma is controversially discussed in the literature and further studies are required [22].
The frequency of cervical adenocarcinoma is variable, but a prevalence between 15% and 25% is
reported in the current literature [23]. Although the AC is less frequent than the SCC, we think that
an immunohistochemical evaluation of the EP3 receptor could be an interesting tool for the clinical
routine in the future.
In our study next to the EP3 receptor we found the T-status, the histology and the N-status
to be an independent marker of overall survival. To our knowledge, this is the first time that
associations of EP3 receptor with other biological characteristics of cervical cancer and the effect
of EP3 on survival of cervical cancer patients have been analysed. We could not find another report
describing EP3 as an independent prognosticator for long time survival in cervical cancer patients.
Other independent markers for overall survival in patients with cervical cancer have also been
investigated by Beyer et al. [16]. They found the histone H3 acetyl K9 to be an independent marker of
overall survival. Chen et al. supposed that cervical carcinoma high-expressed long non coding RNA 1
(lncRNA-CCHE1) is an independent poor prognostic biomarker [24].
The role of EP3 and cancer in other studies show various effects. Some studies demonstrate
an indirect pro-tumorigenic effect of EP3 receptor expression in various kinds of cancer, which was
similar to our data. Miyata et al. have shown that the density of EP3 receptor positive stromal
cells is associated with cancer cell progression and malignant potential, including angiogenesis and
lymphangiogenesis [25]. The EP3 receptor has been shown to contribute to malignant aggressiveness,
carcinogenesis and poor prognosis in several cancer types like lung adenocarcinoma and breast
carcinoma [26]. On the contrary, other studies suggest an anti-tumorigenic effect of EP3 receptor
expression. Shoji et al. show a colon tumour development in EP3 receptor knockout mice and suggest
an important role of EP3 in suppression of cell growth [27]. Another study shows that an upregulation
of EP3 expression in prostate cancer cells has preventive and anticancer effects [28,29].
Important to respect is the fact that we have different isoforms of the EP3 receptor. Many details
of the EP3 receptor and its isoforms are uncovered and the data have a number of discrepancies,
especially with regard to its effects [12]. The isoforms of the EP3 receptor may have different effects
and physiological roles based on the tissue, in which they are expressed [12]. Thus, further studies are
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required to investigate the PGE2/EP3 isoforms for a better understanding of the physiological and
pathophysiological effects.
4. Materials and Methods
4.1. Patients and Specimens
In this study, cervical cancer tissue samples of 250 patients who underwent surgery
for cervical cancer from 1993 to 2002 at the Department of Gynecology and Obstetrics,
Ludwig-Maximilians-University of Munich, Germany were used. The patient’s median age was
47 years (range 20–83 years), and overall median survival was 100 months. The distribution of
clinic-pathological variables can be seen in Table 3. In our study patients with squamous cell carcinoma
or adenocarcinoma of the cervix were included, other histological subtypes were excluded due to the
low number. No pre-selection besides that took place. As a positive control for immunohistochemical
staining, we utilized ovarian carcinoma metastasis of the colon tissue for EP3 which was received
from the Department of Obstetrics and Gynecology of the Ludwig-Maximilians-University of Munich.
The Munich Cancer Registry (MCR) provided clinical and follow-up data for statistical analyses and
retrieved from medical records. All of this is supported by the Bavarian Cancer Registry act and results
in a loss of 4.4% follow-up patients.
Table 3. Patient characteristics.
Item Numbers/Total Numbers Percentage
Age
<49 139/250 55.6%
>49 111/250 44.4%
Number of positive lymph nodes
0 151/250 60.4%
>1 97/250 38.8%
Not available 2/250 0.8%
pT, Tumour size
pT1 110/250 44,0%
pT2/3/4 137/250 54.8%
Not available 3/250 1.2%
FIGO
I 64/250 25.6%
II/III/IV 92/250 36.8%
Not available 94/250 37.6%
Tumour grade
I 21/250 8.4%
II 143/250 57.2%
III 78/250 31.2%
Not available 8/250 3.2%
Tumour subtype
Squamous 202/250 80.8%
Adenocarcinoma 48/250 19.2%
Progression (over 235 months)
None 210/250 84,0%
At least one event 21/250 11.6%
Not available 11/250 4.4%
Survival (over 235 months)
Right censured 190/250 76,0%
Died 49/250 19.6%
Not available 11/250 4.4%
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4.2. Ethics Approval
The initially collected cervical cancer specimens for histopathological diagnostics were no longer
used for clinical tests. We recruited all patients for this survey out of this histopathological collective.
The data of the patients were totally anonymised. The authors were blinded for clinical
information during statistical analyses, including survival time. The ethics committee of the
Ludwig-Maximilians University approbated the ethical vote of this study. The Helsinki Declaration
guidelines were respected (reference number 259-16, 13 June 2016).
4.3. Immunohistochemistry
The paraffin-embedded and formalin-fixed samples were cut (3 µm) from all specimens and
mounted on positively charged glass slides. Stored at +20 ◦C before dewaxing for 20 min in xylol
was performed. After washing the tissue in 100% ethanol, the endogenous peroxidase was blocked
with 3% methanol/H2O2 for 20 min. The tumour slides were rehydrated in a descending alcohol
series. To unmask the antigen after formalin-fixation-associated protein-agglomeration, the slides were
warmed up in an airtight pot for 5 min at +100 ◦C, adding a trisodium citrate buffer solution (Merck 244
and Merck 6448) with pH = 6. After preparing the slides by washing them in distilled water and
PBS-buffer the first step of the Polymer kit (ZytoChem Plus HRP Polymer System, Berlin, Germany)
was applied for 5 min to avoid unspecific (hydrophobic) bindings. Incubation of the samples at
+4 ◦C for 16 h with the EP3 primary antibody (anti-PTGER3 antibody polyclonal rabbit IgG; ABCAM
ab189131) followed. After steps 2 and 3 of the polymer kit (Reagents 2 and 3), the substrate-staining
with DAB (chromogen substrate kit, Dako, Munich, Germany) was performed for two and a half
minutes, followed by the counterstaining by hemalaun colouring (2 min). The samples were finally
dehydrogenated in an ascending alcohol series and covered.
5. Conclusions
In this study we showed that the immunohistochemical evaluation of the EP3 receptor expression
is correlated to the FIGO classification, so we could demonstrate that an increased EP3 receptor
expression correlates with a negative outcome of overall survival of cervical carcinoma patients.
In addition we found a different expression of EP3 in correlation to the histological subtype.
Patients with AC and a high expression of EP3 receptor had a significant worse outcome regarding
survival. Targeting the EP3 receptor diagnostically seems generally possible.
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